Health Care • Biotechnology: Pharmaceutical Preparations
$61.39 ▲ +0.82
(+1.35%)
MKT CAP: $125.40B • VOL: 14.77M
52W L $45 52W H $69
BMY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $48.19B | $48.30B | $45.01B |
| YoY Revenue Growth % | -0.2% | +7.3% | — |
| Gross Profit | $34.26B | $34.33B | $19.80B |
| Gross Margin % | 71.1% | 71.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $8.32B | -$10.56B | $9.47B |
| Operating Margin % | 17.3% | -21.9% | 21.0% |
| Net Income (GAAP) | $7.05B | -$8.95B | $8.03B |
| EBITDA (Normalized) | $9.37B | -$9.56B | $11.09B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $14.16B | $15.19B | $13.86B |
| Capital Expenditures (CapEx) | $1.31B | $1.25B | $2.03B |
| Free Cash Flow (FCF) | $12.85B | $13.94B | $11.83B |
| FCF Margin % | 26.7% | 28.9% | 26.3% |
| Return on Invested Capital (ROIC %) | 12.9% | -15.6% | 18.0% |
| Cash & Short-Term Equivalents | $10.21B | $10.35B | $7.59B |
| Total Debt (Short + Long Term) | $42.85B | $47.60B | $16.14B |
| Total Stockholders' Equity | $18.47B | $16.34B | $33.11B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BMY.